Vestipitant/Paroxetine

维替匹坦/帕罗西汀

Report date: 2022/07/19 16:22:54

Base Information

Drug NameVestipitant/Paroxetine
Drug Alias Name维替匹坦+帕罗西汀Paroxetine/Vestipitant帕罗西汀/维替匹坦GW-597599+paroxetine597599+paroxetine +[17] 
ClassificationSmall molecules
Mechanisms of ActionNeurokinin 1 receptor antagonistsSerotonin transporter inhibitors
TargetsNeurokinin 1 receptorSerotonin transporter
Therapy Area/IndicationsDepressive DisorderPhobia, SocialAnxiety Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenNorwaySouth Africa +[5] 
CombinationsYes Paroxetine hydrochlorideVestipitant Mesylate
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsDepressive DisorderPhobia, SocialAnxiety Disorders

Other Information

ATC CodeN/A
Related LinksN/A